- Home
- MGRX vs SYRS Comparison
MGRX vs SYRS Comparison
Compare MGRX & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- SYRS
- Stock Information
- Founded
- MGRX 2021
- SYRS 2011
- Country
- MGRX United States
- SYRS United States
- Employees
- MGRX N/A
- SYRS N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- SYRS Health Care
- Exchange
- MGRX Nasdaq
- SYRS Nasdaq
- Market Cap
- MGRX 6.3M
- SYRS 7.1M
- IPO Year
- MGRX 2023
- SYRS 2016
- Fundamental
- Price
- MGRX $2.61
- SYRS $0.22
- Analyst Decision
- MGRX
- SYRS Hold
- Analyst Count
- MGRX 0
- SYRS 5
- Target Price
- MGRX N/A
- SYRS $3.00
- AVG Volume (30 Days)
- MGRX 96.9K
- SYRS 3.2M
- Earning Date
- MGRX 11-14-2024
- SYRS 10-31-2024
- Dividend Yield
- MGRX N/A
- SYRS N/A
- EPS Growth
- MGRX N/A
- SYRS N/A
- EPS
- MGRX N/A
- SYRS N/A
- Revenue
- MGRX $755,000.00
- SYRS $386,000.00
- Revenue This Year
- MGRX N/A
- SYRS N/A
- Revenue Next Year
- MGRX N/A
- SYRS N/A
- P/E Ratio
- MGRX N/A
- SYRS N/A
- Revenue Growth
- MGRX 52.20
- SYRS N/A
- 52 Week Low
- MGRX $2.07
- SYRS $0.18
- 52 Week High
- MGRX $16.80
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- MGRX 52.13
- SYRS 37.85
- Support Level
- MGRX $2.07
- SYRS $0.20
- Resistance Level
- MGRX $2.77
- SYRS $0.25
- Average True Range (ATR)
- MGRX 0.17
- SYRS 0.04
- MACD
- MGRX 0.01
- SYRS 0.03
- Stochastic Oscillator
- MGRX 77.70
- SYRS 21.90
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.